Is It Time To Accumulate AstraZeneca plc Shares?

AstraZeneca plc’s (LON: AZN) dual growth strategy could deliver for investors in the long run.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sometimes — most of the time, in fact — good investing decisions seem to boil down to the qualitative judgements we make more than the way we scrutinise a firm’s financial numbers.

I would argue that we need a good dollop of art as well as a smattering of science to excel in the game of investment.

A feeling in my bones

Much of the time, I seem to end up looking for clues to a firm’s potential, rather than hard facts and figures.

Take AstraZeneca now, for example. Based on the numbers alone, it would be easy to write the firm off as a dull potential investment and to move on to something more obviously exciting. At today’s share price of 4203p, the firm trades on a forward price-to-earnings (P/E) ratio of about 16 for 2016. City analysts following the firm expect earnings to slide 4% that year and those reduced earnings to cover a dividend payout just under one-and-a-half times for a yield of 4.3%.

Based on the numbers alone, AstraZeneca is not a growth proposition, but it is not a value proposition either. The firm has some attractions as a ‘defensive’-style investment in a nice, safe sector with consumer-product attractions and stable cash flow, and it is a big beast for sure. So, we might buy the shares believing the dividend payout to be safe and secure.

However, I have a feeling in my bones that AstraZeneca might be building up a head of steam for a sustainable growth spurt down the line, and recent news seems to provide tantalising clues that that feeling could be right.

A dual growth strategy

In the news today is AstraZenca’s announcement regarding the firm’s recent $6 billion bond issue. The company plans to use the proceeds of the issue to fund its acquisition of ZS Pharma, Inc. The directors reckon ZS Pharma is a good fit with AstraZeneca’s pipeline and portfolio in the area of cardiovascular and metabolic disease.

Firms don’t look for acquisitions unless they are seeking growth, so I see this development as a clue to AstraZeneca’s growth potential from here. The pharmaceutical industry is notoriously opaque. You could spend a week trying to explain to me the significance of what AstraZeneca gets with this acquisition and still not get through the fug between my ears. In many ways, I don’t need to understand too much, though, to make a successful investment.

What matters is that AstraZeneca’s directors see the value in the deal. The qualitative judgements I need to make surround the characteristics of the industry itself and whether or not I trust the management team at AstraZeneca.

AstraZeneca has a track record of developing blockbuster drugs organically, and as long as the firm keeps reinvesting into research and development there is every chance that new formulations will rise to boost earnings in the future. On top of that, the firm enhances its pipeline by combining well-targeted acquisitions. Such organic and acquisitive development strikes me as a dual growth strategy that could deliver for investors in the long run.

Is this a buying opportunity?

While we are waiting for growth to materialise, AstraZeneca offers, arguably, one of the safest dividends in the FTSE 100. With analysts yet to pencil in earnings upgrades, right now could end up looking like a good buying opportunity for those interested in AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »